Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Bristol Myers Squibb Co / Equity Bottom-Up

<ul><li>Bristol-Myers Squibb’s first quarter of 2026 demonstrated a moderate overall revenue increase of 1% year-over-year, reaching approximately $11.5 billion.</li><li>The company’s growth portfolio experienced a more notable 9% rise, driven by key products such as Reblozyl, Breyanzi, Camzyos, Opdualag, Qvantig, and Cobenfy.</li><li>Eliquis, a major product, posted a 13% revenue increase to around $4.1 billion despite price reductions implemented at the start of the year, reflecting strong demand albeit accompanied by wholesaler inventory adjustments.</li></ul>

Bristol-Myers Squibb’s first quarter of 2026 demonstrated a moderate overall revenue increase of 1% year-over-year, reaching approximately $11.5 billion.The company’s growth portfolio experienced a more notable 9% rise, driven by key products such as Reblozyl, Breyanzi, Camzyos, Opdualag, Qvantig, and Cobenfy.Eliquis, a major product, posted a 13% revenue increase to around $4.1 billion despite price reductions implemented at the start of the year, reflecting strong demand albeit accompanied by wholesaler inventory adjustments.

Bristol Myers Squibb: Safer Blood Thinners

<ul><li>Bristol-Myers Squibb reported solid financial and operational results for full-year 2025, reflecting steady progress in reshaping its portfolio toward sustained growth.</li><li>The company’s growth portfolio expanded by 17% for the year and 15% in the fourth quarter, nearly offsetting an approximate $4 billion revenue decline in its legacy portfolio.</li><li>Notable contributors were recently launched products including Opdualag, Breyanzi, Camzyos, and Reblozyl—each exceeding $1 billion in full-year sales, with Reblozyl surpassing $2 billion.</li></ul>

Bristol-Myers Squibb reported solid financial and operational results for full-year 2025, reflecting steady progress in reshaping its portfolio toward sustained growth.The company’s growth portfolio expanded by 17% for the year and 15% in the fourth quarter, nearly offsetting an approximate $4 billion revenue decline in its legacy portfolio.Notable contributors were recently launched products including Opdualag, Breyanzi, Camzyos, and Reblozyl—each exceeding $1 billion in full-year sales, with Reblozyl surpassing $2 billion.

Bristol Myers Squibb: Admilparant’s Pulmonary Fibrosis Bet—A Breakthrough Opportunity or Clinical Risk?

<ul><li>Bristol-Myers Squibb Co. reported its third-quarter 2025 financial results, highlighting strong performance across its growth portfolio and maintaining focus on its long-term growth strategy.</li><li>The company's revenue reached approximately $12.2 billion, driven by a 17% increase in sales from its growth portfolio, which includes key drugs such as Opdivo, Reblozyl, Camzyos, and Breyanzi.</li><li>Given these strong results, Bristol-Myers Squibb has raised its full-year revenue guidance, highlighting confidence in its current portfolio.</li></ul>

Bristol-Myers Squibb Co. reported its third-quarter 2025 financial results, highlighting strong performance across its growth portfolio and maintaining focus on its long-term growth strategy.The company's revenue reached approximately $12.2 billion, driven by a 17% increase in sales from its growth portfolio, which includes key drugs such as Opdivo, Reblozyl, Camzyos, and Breyanzi.Given these strong results, Bristol-Myers Squibb has raised its full-year revenue guidance, highlighting confidence in its current portfolio.

Bristol-Myers Squibb Just Got Crucial FDA Backing On Alzheimer’s Psychosis Program; What's NEXT?

<ul><li>Bristol Myers Squibb has once again found itself in the spotlight for all the wrong reasons, with the company announcing that it has halted a Phase 3 trial of its experimental blood thinner, milvexian.</li><li>The trial, which targeted patients recovering from acute coronary syndrome, was deemed unlikely to meet its primary endpoint by an independent data monitoring committee.</li><li>The news, which broke on November 14, 2025, led to a 3.1% drop in BMY shares, contributing to a year-to-date decline of 17%.</li></ul>

Bristol Myers Squibb has once again found itself in the spotlight for all the wrong reasons, with the company announcing that it has halted a Phase 3 trial of its experimental blood thinner, milvexian.The trial, which targeted patients recovering from acute coronary syndrome, was deemed unlikely to meet its primary endpoint by an independent data monitoring committee.The news, which broke on November 14, 2025, led to a 3.1% drop in BMY shares, contributing to a year-to-date decline of 17%.

Bristol Myers Crashes Again: Another Trial Failure Shocks Investors

<ul><li>Bristol-Myers Squibb's (BMS) Q3 2025 results reflect a mixed performance, characterized by robust growth in its new portfolio and strategic shifts, but also by challenges from legacy products.</li><li>The company's growth portfolio demonstrated strong sales, with a 17% increase year-over-year.</li><li>Growth was primarily driven by their immuno-oncology (IO) products, Reblozyl, Camzyos, and Breyanzi.</li></ul>

Bristol-Myers Squibb's (BMS) Q3 2025 results reflect a mixed performance, characterized by robust growth in its new portfolio and strategic shifts, but also by challenges from legacy products.The company's growth portfolio demonstrated strong sales, with a 17% increase year-over-year.Growth was primarily driven by their immuno-oncology (IO) products, Reblozyl, Camzyos, and Breyanzi.

Bristol-Myers Squibb Is Betting Big on Cobenfy — Could This Be the Next Blockbuster Drug?

United States

Bristol-Myers Squibb Company is a global biopharmaceutical company. The Company develops, licenses, manufactures, markets, and sells pharmaceutical and nutritional products. Bristol-Myers Squibb products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant  rejection, and psychiatric disorders.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Bristol Myers Squibb Co (BMY US)

Bristol Myers Squibb: Safer Blood Thinners

Bristol-Myers Squibb’s first quarter of 2026 demonstrated a moderate overall revenue increase of 1% year-over-year, reaching approximately $11.5...

Baptista Research

Bristol Myers Squibb: Admilparant’s Pulmonary Fibrosis Bet—A Breakthrough Opportunity or Clinical Risk?

Bristol-Myers Squibb reported solid financial and operational results for full-year 2025, reflecting steady progress in reshaping its portfolio...

Baptista Research

Bristol-Myers Squibb Just Got Crucial FDA Backing On Alzheimer’s Psychosis Program; What's NEXT?

Bristol-Myers Squibb Co. reported its third-quarter 2025 financial results, highlighting strong performance across its growth portfolio and...

Baptista Research

Bristol Myers Crashes Again: Another Trial Failure Shocks Investors

Bristol Myers Squibb has once again found itself in the spotlight for all the wrong reasons, with the company announcing that it has halted a...

Baptista Research

Bristol-Myers Squibb Is Betting Big on Cobenfy — Could This Be the Next Blockbuster Drug?

Bristol-Myers Squibb's (BMS) Q3 2025 results reflect a mixed performance, characterized by robust growth in its new portfolio and strategic...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)